COMMUNIQUÉS West-GlobeNewswire
-
Applied Biologics Announces Publication of New XWRAP® Translational Research Demonstrating More Favorable Wound-Healing Biology
24/09/2026 -
Autonomix Medical Expands Global Intellectual Property Footprint with European Patent Supporting Precision Neuromodulation Platform
24/09/2026 -
Elliston Health Launches Concierge Medicine for Adults in New York City
24/09/2026 -
Avaí Bio and Austrianova Present Encapsulated Cell Approach to Sustained α-Klotho Delivery at 2026 Klotho Conference
24/09/2026 -
Free Community Cookout in Frisco: Ally Medical ER Ribbon Cutting
24/09/2026 -
Parents in Distress: New Survey Highlights the Impact of Lost Sleep on Busy Parents
24/09/2026 -
Medevise Consulting to Host “Robotics in Ophthalmology” Workshop in New Orleans During AAO 2026
24/09/2026 -
Persevere Therapeutics Announces Treatment of First Patient in its MIROC-1 Phase 2a Ovarian Cancer Clinical Trial
24/09/2026 -
Kessler Foundation and UPnRIDE Launch Research Initiative to Advance What’s Possible for People with Disabilities
24/09/2026 -
SK pharmteco Launches Catalyst Kit to Streamline Catalytic Reaction Development and Continuous Manufacturing Scale-Up
24/09/2026 -
Celularity Announces Over $10 Million Initial Financing Closing as Part of Up to $28 Million Recapitalization to Accelerate Growth Following Significant Operating Improvements
24/09/2026 -
ŌURA Joins Workday Wellness, Giving Employers a New Way to Fund Oura Ring as a Flexible Benefit
24/09/2026 -
Kasvu Therapeutics Raises €30 Million Series A Financing Round led by Hadean Ventures to Advance its Novel TrkB Potentiator into Clinical Development Targeting Neuropsychiatric Disorders
24/09/2026 -
Coloplast A/S - Financial Calendar 2026/27
24/09/2026 -
Adventure With a Purpose: A Race Against Blindness Unveils Adventure Package Fundraiser Valued at $350,000
24/09/2026 -
Biodesix Advances Two Complementary Approaches to Molecular Residual Disease (MRD) Monitoring
24/09/2026 -
aTyr Pharma Announces Alignment with FDA on Phase 3 Study of Efzofitimod in Pulmonary Sarcoidosis
24/09/2026 -
MediciNova Announces Completion of Last Patient, Last Visit in the Double-Blind Portion of the Phase 2b/3 COMBAT-ALS Trial of MN-166 (Ibudilast)
24/09/2026 -
Kyverna Therapeutics Reports Positive One-Year Data Demonstrating Durable Clinical Responses and Favorable Safety Profile for Miv-cel in Stiff Person Syndrome and Generalized Myasthenia Gravis
24/09/2026
Pages